Oramed to re­view strate­gic al­ter­na­tives, cloud­ing path for­ward for oral in­sulin

Oramed Phar­ma­ceu­ti­cals will look at strate­gic al­ter­na­tives af­ter the biotech’s at­tempt at cre­at­ing an in­sulin pill fal­tered in a Phase III last month.

The New York biotech is still min­ing through the da­ta from the Phase III of OR­MD-0801, the fail­ure of which tanked the stock by 70% in Jan­u­ary. But to move for­ward, the board and ex­ec­u­tives are tak­ing a fine look at the pipeline and “con­duct­ing a com­pre­hen­sive re­view of strate­gic al­ter­na­tives” that could in­clude sell­ing the busi­ness or its as­sets.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER